Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (19)

2024

  1. Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort

    Clinical Kidney Journal, Vol. 17, Núm. 8

  2. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports, Vol. 9, Núm. 5, pp. 1419-1428

  3. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis

    Nephrology Dialysis Transplantation, Vol. 39, Núm. 2, pp. 328-340

2023

  1. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  2. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

  3. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)

    Clinical Kidney Journal, Vol. 16, Núm. 9, pp. 1384-1402

  4. Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1596-1604

2022

  1. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  2. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  2. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease

    Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298

2019

  1. IgA nephropathy in elderly patients

    Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 8, pp. 1183-1192

2018

  1. CD19+ B-cells, a new biomarker of mortality in hemodialysis patients

    Frontiers in Immunology, Vol. 9, Núm. JUN

  2. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis

    Clinical Journal of the American Society of Nephrology, Vol. 13, Núm. 12, pp. 1851-1858

2017

  1. Remission of hematuria improves renal survival in IgA nephropathy

    Journal of the American Society of Nephrology, Vol. 28, Núm. 10, pp. 3089-3099

2014

  1. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  2. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

1987

  1. Treatment of Hemodialysis-Related Porphyria Cutanea Tarda with Deferoxamine

    New England Journal of Medicine